TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10450715

Group type: EXPERIMENTAL
Intervention: Nitrendipine (10-40 mg/d) with possible addition of enalapril (5-20 mg/d) and/or hydrochlorothiazide (12.5-25.0 mg/d)
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study: 8524699

Group type: EXPERIMENTAL
Intervention: Nifedipine monotherapy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Combined therapy with nifedipine and metoprolol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 47
Study: 2331067

Group type: EXPERIMENTAL
Intervention: Oropharyngeal airway
Number of subjects: 203

Group type: COMPARATOR
Intervention: Gauze bite-block
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Blood noted on airway instruments
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: No blood noted on airway instruments
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Intubation by an anesthesia resident with less than 1 yr experience
Number of subjects: 203
Study: 487688

Group type: EXPERIMENTAL
Intervention: Atenolol, 50 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol, 80 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol, 160 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Propranolol, 640 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Atenolol, 200 mg daily
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Atenolol, 400 mg daily
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 30924169

Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 76
Study: 27997267

Group type: EXPERIMENTAL
Intervention: RF Group (n = 16)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: RF and LLLT Group (n = 15)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control Group (n = 15)
Number of subjects: 46
Study: 25832578

Group type: EXPERIMENTAL
Intervention: Tuebinger-Intensiv-Programm für Eltern (Tipe)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 0
Study: 24227718

Group type: EXPERIMENTAL
Intervention: Retinal imaging combined with behavioral measurements
Number of subjects: 0
Study: 21362276

Group type: EXPERIMENTAL
Intervention: PCPS-MNC-CM from DE group
Number of subjects: 25

Group type: COMPARATOR
Intervention: PCPS-MNC-CM from EU group
Number of subjects: 25
Study: 20011596

Group type: EXPERIMENTAL
Intervention: HIV-1-infected partners with HSV-2-seropositive status
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Presence of STI in partner
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Unprotected sex
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Low education
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: HSV-2 status in HIV-1-uninfected participants
Number of subjects: 416
Study: 16970952

Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 351

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 351
Study: 14982562

Group type: EXPERIMENTAL
Intervention: Propofol 60 mg ml(-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol 10 mg ml(-1)
Number of subjects: 20
Study: 11354206

Group type: EXPERIMENTAL
Intervention: 1% lignocaine 0.1 ml via a 27 gauge needle and diabetic syringe before cannulation
Number of subjects: 322

Group type: COMPARATOR
Intervention: Saline substituted for lignocaine
Number of subjects: 322

Group type: COMPARATOR
Intervention: Immediate cannulation without local anaesthetic
Number of subjects: 322
Study: 9149896

Group type: EXPERIMENTAL
Intervention: Physician-delivered, self-help intervention to reduce fat and increase fiber intake
Number of subjects: 1795

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1795
Study: 7536155

Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 120 and 30 min before EST and four hours after
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 151
Study: 30121588

Group type: EXPERIMENTAL
Intervention: 5+ live births
Number of subjects: 40687

Group type: COMPARATOR
Intervention: 0 prior pregnancies
Number of subjects: 40687

Group type: EXPERIMENTAL
Intervention: 1 prior pregnancy
Number of subjects: 40687

Group type: EXPERIMENTAL
Intervention: 2-4 prior pregnancies
Number of subjects: 40687

Group type: EXPERIMENTAL
Intervention: Reproductive Duration (RD)
Number of subjects: 40687
Study: 27901556

Group type: EXPERIMENTAL
Intervention: ProTaper Universal retreatment (PTUR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Mtwo R
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: D‐RaCe
Number of subjects: 36
Study: 25404215

Group type: EXPERIMENTAL
Intervention: Text message intervention (SMS sent at h48, D7, D15 and monthly)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 0
Study: 23740148

Group type: EXPERIMENTAL
Intervention: Early lactate normalization during the first 6 hours of resuscitation
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Lactate clearance ≥ 50%
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Lactate clearance ≥ 10%
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Initial lactate level
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Relative lactate clearance
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Lactate clearance rate
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 187
Study: 20886733

Group type: EXPERIMENTAL
Intervention: Transcranial bitemporal magnetotherapy (TcMT) combined with reduced basic therapy (driptan 2.5 mg twice a day)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo TcMT with basic therapy
Number of subjects: 58
Study: 18997262

Group type: EXPERIMENTAL
Intervention: Proposed regularization-based algorithm for IMRT planning
Number of subjects: 2

Group type: COMPARATOR
Intervention: Equal number of four segments for each field (control)
Number of subjects: 2
Study: 16648332

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Sertraline (N=14 overweight and obese subjects)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (N=14 overweight and obese subjects)
Number of subjects: 34
Study: 12953327

Group type: EXPERIMENTAL
Intervention: Transdermal patches releasing estradiol (E2) and progestogen for HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal contraceptive patches delivering ethinyl E2 and norelgestromin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone patches for hypogonadal men
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal delivery of reproductive steroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal systems
Number of subjects: 0
Study: 10811676

Group type: EXPERIMENTAL
Intervention: Topotecan 1.25 mg/m(2)/d PO x 5 preceded by cisplatin 75 mg/m(2) IV day 1
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Topotecan 2.0 mg/m(2)/d PO followed by cisplatin 75 mg/m(2) IV day 5
Number of subjects: 49

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m(2) IV
Number of subjects: 49
Study: 8800169

Group type: EXPERIMENTAL
Intervention: Simultaneous tepid cardioplegia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Alternate tepid cardioplegia
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Simultaneous cardioplegia
Number of subjects: 60
Study: 1727803

Group type: EXPERIMENTAL
Intervention: Infusion of insulin (30 IU) and glucagon (3 mg) for 12 hr/day during a 3-week period
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control group received an infusion of glucose for 12 hr/day during a 3-week period
Number of subjects: 72
Study: 3977401

Group type: EXPERIMENTAL
Intervention: Human milk supplemented with human milk protein
Number of subjects: 35

Group type: COMPARATOR
Intervention: Human milk alone
Number of subjects: 35
Study: 29710797

Group type: EXPERIMENTAL
Intervention: Eyeglasses voucher program (subsidy voucher redeemable for a free pair of prescription eyeglasses)
Number of subjects: 13100

Group type: COMPARATOR
Intervention: No subsidy (control group)
Number of subjects: 13100
Study: 27391911

Group type: EXPERIMENTAL
Intervention: Lifeline ARM chest compression system (ARM; Defibtech)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard BLS (manual chest compressions)
Number of subjects: 37
Study: 25244317

Group type: EXPERIMENTAL
Intervention: Zirconia abutments (test)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Titanium abutments (control)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 22453589

Group type: EXPERIMENTAL
Intervention: Zinc citrate 50 mg and phytase 3,000 PU
Number of subjects: 77

Group type: COMPARATOR
Intervention: Lactulose placebo
Number of subjects: 77

Group type: COMPARATOR
Intervention: Zinc gluconate 10 mg
Number of subjects: 77
Study: 19536077

Group type: EXPERIMENTAL
Intervention: Improved chimney stove
Number of subjects: 1047

Group type: COMPARATOR
Intervention: Control group (traditional cooking methods)
Number of subjects: 1047
Study: 18549938

Group type: EXPERIMENTAL
Intervention: Raloxifen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 16179086

Group type: EXPERIMENTAL
Intervention: Laminin chains in allergic asthmatics
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Laminin chains in non-allergic asthmatics
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study: 12385443

Group type: EXPERIMENTAL
Intervention: 125 mg SP-303
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 250 mg SP-303
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: 500 mg SP-303
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 10102461

Group type: EXPERIMENTAL
Intervention: APTT screening in patients on OAT
Number of subjects: 734
Study: 8703649

Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mu kg‐1 min‐1) during hypoxaemia (SpO2 80%)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Incremental hypoxaemia (SpO2 90, 85, 80%)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control arm (no propranolol) during hypoxaemia
Number of subjects: 12
Study: 2185701

Group type: EXPERIMENTAL
Intervention: Turbuhaler inhaler at inhalation rates slower than 28 1/minute
Number of subjects: 72

Group type: COMPARATOR
Intervention: Turbuhaler inhaler
Number of subjects: 72
Study: 87092

Group type: EXPERIMENTAL
Intervention: FPL 57787 6 mg four times a day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 31646806

Group type: EXPERIMENTAL
Intervention: Docetaxel + Cisplatin (DTX+DDP)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Paclitaxel + Cisplatin (TAX+DDP)
Number of subjects: 90
Study: 29997169

Group type: EXPERIMENTAL
Intervention: PACT (Plans for Action and Care Transitions) intervention
Number of subjects: 147

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 147
Study: 26702601

Group type: EXPERIMENTAL
Intervention: Mindful attention induction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard food-cue exposure
Number of subjects: 40
Study: 24573385

Group type: EXPERIMENTAL
Intervention: FLT3 mutation
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: NPM1c mutation
Number of subjects: 1312

Group type: EXPERIMENTAL
Intervention: Multi-parameter prognostic risk score with molecular information
Number of subjects: 1312
Study: 22914405

Group type: EXPERIMENTAL
Intervention: 16‐French resectoscope
Number of subjects: 401

Group type: COMPARATOR
Intervention: 22‐French resectoscope
Number of subjects: 401

Group type: COMPARATOR
Intervention: 15‐French hysteroscope
Number of subjects: 401
Study: 20582906

Group type: EXPERIMENTAL
Intervention: 120 mg Ginkgo extract (EGb 761)
Number of subjects: 3069

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3069
Study: 18026906

Group type: EXPERIMENTAL
Intervention: Weekly gemcitabine (125 mg/m(2)) with cisplatin (40 mg/m(2)) and pelvic radiotherapy
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Cisplatin dosage reduction to 20 mg/m(2)
Number of subjects: 7
Study: 16121513

Group type: EXPERIMENTAL
Intervention: KanJang oral solution (fixed combination of Echinacea purpurea, Adhatoda vasica, and Eleutherococcus senticosus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Echinacea mixture (Echinacea purpurea and Eleutherococcus senticosus)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (Bromhexine)
Number of subjects: 0
Study: 12586521

Group type: EXPERIMENTAL
Intervention: Perceived voluntary contraction efforts at levels 1-9 on an 11-point scale (0-10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vastus medialis (VM) EMG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Peak torque (PT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Average torque (AT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Torque coefficient of variation (C.V.)
Number of subjects: 30
Study: 10609984

Group type: EXPERIMENTAL
Intervention: d-amphetamine (indirect dopamine agonist)
Number of subjects: 0
Study: 8953999

Group type: EXPERIMENTAL
Intervention: ED vaccination group (n = 611)
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: Letter group (n = 610)
Number of subjects: 1835

Group type: COMPARATOR
Intervention: Control group (n = 614)
Number of subjects: 1835

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 1835
Study: 2002251

Group type: EXPERIMENTAL
Intervention: Digital intradermal injections of histamine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital intradermal injections of substance P
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital intradermal injections of calcitonin gene‐related peptide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Digital intradermal injections of saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Digital intradermal injections of compound 48/80
Number of subjects: 0
Study: 6760678

Group type: EXPERIMENTAL
Intervention: Metoprolol (100-300 mg/day)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pindolol (5-15 mg/day)
Number of subjects: 0
Study: 30665440

Group type: EXPERIMENTAL
Intervention: First line ART
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Second line ART
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Continuous ART adherence education
Number of subjects: 30
Study: 26684670

Group type: EXPERIMENTAL
Intervention: MOTR treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Comparison treatment
Number of subjects: 40
Study: 25885650

Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg daily for 24 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (daily for 24 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Escitalopram and Placebo (both groups)
Number of subjects: 29
Study: 24335363

Group type: EXPERIMENTAL
Intervention: UFT/PSK
Number of subjects: 205

Group type: COMPARATOR
Intervention: UFT
Number of subjects: 205
Study: 20632194

Group type: EXPERIMENTAL
Intervention: Transjugular intrahepatic portosystemic shunt (TIPS)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Large-volume paracentesis plus albumin
Number of subjects: 60
Study: 19567211

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose dexamethasone (HDD)
Number of subjects: 0
Study: 17901034

Group type: EXPERIMENTAL
Intervention: Nepafenac 0.1%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ketorolac 0.4%
Number of subjects: 40
Study: 15131767

Group type: EXPERIMENTAL
Intervention: Fat group - standard meal plus a fat supplement of 300 kcal from different types of fat (butter, sunflower margarine, olive oil)
Number of subjects: 39

Group type: COMPARATOR
Intervention: CHO group - standard meal plus a supplement of 300 kcal from different types of CHO (bread, coke, fruit)
Number of subjects: 39
Study: 10797515

Group type: EXPERIMENTAL
Intervention: Acoustic rhinometry measurements
Number of subjects: 20
Study: 9007706

Group type: EXPERIMENTAL
Intervention: Prednisolone followed by lymphoblastoid interferon
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo followed by lymphoblastoid interferon
Number of subjects: 213
Study: 1649018

Group type: EXPERIMENTAL
Intervention: 99mTc(v) DMSA planar scintigraphy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CT (computerized tomography)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: 99mTc(v) DMSA scintigraphy
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 26
Study: 6832119

Group type: EXPERIMENTAL
Intervention: 0.75 ppm SO2 during heavy exercise with mouthpiece breathing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 0.75 ppm SO2 during heavy exercise with unencumbered breathing
Number of subjects: 23

Group type: COMPARATOR
Intervention: Clean air exposures
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mouthpiece breathing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Unencumbered breathing
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Mouthpiece breathing with SO2
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Unencumbered breathing with SO2
Number of subjects: 23
Study: 30917899

Group type: EXPERIMENTAL
Intervention: VTE-BLEED score ≥2 points
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: GFR <30 ml/min/1.73 m2
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Previous surgery
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin as initial treatment
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 522
Study: 30047376

Group type: EXPERIMENTAL
Intervention: Mosaic Ad26/Ad26 plus high-dose gp140 boost vaccine
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Mosaic Ad26/Ad26 plus low-dose gp140 boost vaccine
Number of subjects: 393

Group type: COMPARATOR
Intervention: Control group (0.9% saline)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Mosaic Ad26/Ad26 plus gp140 boost vaccine in rhesus monkeys
Number of subjects: 393
Study: 25901480

Group type: EXPERIMENTAL
Intervention: Duloxetine + opioid
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo + opioid
Number of subjects: 68
Study: 22288979

Group type: EXPERIMENTAL
Intervention: 3-month posttreatment window (first 90 days after the intervention)
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: 90 days from the end of treatment
Number of subjects: 467

Group type: EXPERIMENTAL
Intervention: 3-month TLFB follow-up time frame
Number of subjects: 467
Study: 20663130

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 199

Group type: COMPARATOR
Intervention: Imipenem/cilastatin
Number of subjects: 199
Study: 18367653

Group type: EXPERIMENTAL
Intervention: Infusion of ANG II (5.0 ng.kg(‐1).min(‐1)) in PA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Infusion of ANG II (5.0 ng.kg(‐1).min(‐1)) in NC
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Simultaneous infusion of nitroprusside and ANG II in PA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Simultaneous infusion of nitroprusside and ANG II in NC
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Unilateral adrenalectomy in PA
Number of subjects: 25
Study: 15776134

Group type: COMPARATOR
Intervention: Azathioprine (AZA) started at 1 mg/kg/day, titrated to 2.5 mg/kg/day after TPMT assay not performed (group 1)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) started at 2.5 mg/kg/day after TPMT assay performed (group 2)
Number of subjects: 29
Study: 12457784

Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg per day)
Number of subjects: 5804

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5804
Study: 10590386

Group type: EXPERIMENTAL
Intervention: Audiocassette recording of consultation
Number of subjects: 60

Group type: COMPARATOR
Intervention: No audiocassette recording
Number of subjects: 60
Study: 8869807

Group type: EXPERIMENTAL
Intervention: Paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Docetaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tomudex
Number of subjects: 0
Study: 1861939

Group type: EXPERIMENTAL
Intervention: Educational intervention (three brief videotapes and written materials)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control (health education videotapes and comparable materials)
Number of subjects: 141
Study: 6485418

Group type: EXPERIMENTAL
Intervention: Orotic acid in combination with clofibrinic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30832598

Group type: EXPERIMENTAL
Intervention: Educational intervention (Group 1)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Educational intervention plus port protector (Group 2)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Observational period (Control)
Number of subjects: 133
Study: 30286798

Group type: EXPERIMENTAL
Intervention: Behavioral intervention of leadership training and problem-solving during daily huddles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (huddles without support or training)
Number of subjects: 0
Study: 27253770

Group type: EXPERIMENTAL
Intervention: Blue light (469 nm)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Amber light (578 nm)
Number of subjects: 35
Study: 24946001

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Cryotherapy (SPC)
Number of subjects: 39
Study: 22753019

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg single dose in young subjects
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Colchicine 0.6 mg single dose in elderly subjects
Number of subjects: 38

Group type: COMPARATOR
Intervention: Comparison of pharmacokinetic parameters between young and elderly subjects
Number of subjects: 38